摘要
目的探讨左卡尼汀联合他莫昔芬对少弱精子症患者的疗效及安全性。方法选择男性少弱精子症患者103例,将其随机分为3组,A组为左卡尼汀及他莫昔芬联合治疗组;B组为左卡尼汀碱治疗组;C组为他莫昔芬治疗组。治疗前及治疗后3个月时对所有病例均进行患者精液参数分析,同时了解配偶妊娠率及不良反应发生情况。结果与治疗前相比,A组患者治疗后精子密度及前向运动精子百分率均明显提高(P<0.01);B组患者治疗后前向运动精子百分率明显提高(P<0.01),精子密度虽有一定提高,但差异无统计学意义(P>0.05);C组患者治疗后精子密度明显提高(P<0.01),但前向运动精子百分率与治疗前相比差异无统计学意义(P>0.05)。治疗3个月后女方妊娠者,A组11例,B组3例,C组4例,A组妊娠率明显高于B组和C组,B、C两组差异无统计学意义。治疗期间所有患者均未见明显不良反应。结论左卡尼汀联合他莫昔芬治疗少弱精子症患者,可以显著改善患者的精子密度和活力,提高其配偶的妊娠率,安全有效。
Objective To investigate the clinical efficacy of L-carnitine combined with tamoxifen in treatment of oligoasthenozoospermia. Methods All 103 patients with oligoasthenozoospermia were randomly divided into three groups including Group A （treated with L-carnitine and tamoxifen）, Group B （treated with L-carnitine） and Group C （treated with tamoxifen）. Semen analysis was done before and after treatment. Side effects as well as pregnant rate were observed. Results Compared with that before treatment, the number of sperms and the percentage of forward motile sperms were all improved significantly in Group A （P〈0.01）; whereas only the percentage of forward motile sperm and only the number of sperms was respectively improved in Group B（P〈0.01） and in Group C（P〈0.01）. The pregnant rate in Group A was higher than that in Group B or Group C （P〈0.05）. No side effects were found in all test patients. Conclusion L-carnitine combined with tamoxifen might be effective and safe in treatment of oligoasthenozoospermia by improving the number of sperm and the percentage of forward motile sperm.
出处
《中国男科学杂志》
CAS
CSCD
2010年第5期55-57,共3页
Chinese Journal of Andrology
基金
河北省人口与计划生育委员会科研项目(项目名称:左旋肉毒碱联合他莫昔芬治疗少弱精子症的研究编号:2008-1308)
